Eisai Dips Toe Into Chinese Generics With TianYi Buy
This article was originally published in PharmAsia News
Executive Summary
Major Japanese innovator Eisai is moving into the Chinese generics sector through the acquisition of the small Chinese firm Liaoning TianYi Biological, in a move it says is designed to tap into strong projected market growth for such products in China.
You may also be interested in...
China Options For Takeda As It Pursues Emerging Markets Buy
Takeda’s recent revelation that it had set aside around $450m for a planned M&A transaction in an undisclosed emerging market has triggered speculation about where and how the company might spend its money. Might China be in the mix?
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.